Edgewise Therapeutics, Inc. (EWTX): Price and Financial Metrics
GET POWR RATINGS... FREE!
EWTX Stock Price Chart Interactive Chart >
EWTX Price/Volume Stats
| Current price | $6.07 | 52-week high | $29.07 |
| Prev. close | $5.76 | 52-week low | $5.41 |
| Day low | $5.56 | Volume | 235,900 |
| Day high | $6.16 | Avg. volume | 326,843 |
| 50-day MA | $8.35 | Dividend yield | N/A |
| 200-day MA | $14.12 | Market Cap | 300.93M |
Edgewise Therapeutics, Inc. (EWTX) Company Bio
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. It offers a precision medicine muscle platform that generates programs to address various muscle disorders, such as Duchenne, Becker, and limb girdle muscular dystrophies. The company develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was founded in 2017 and is headquartered in Boulder, Colorado.
Latest EWTX News From Around the Web
Below are the latest news stories about Edgewise Therapeutics Inc that investors may wish to consider to help them evaluate EWTX as an investment opportunity.
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2021 Financial ResultsBOULDER, Colo., February 24, 2022--Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle disorders, today reported financial results for the fourth quarter and full year of 2021 and recent business highlights. |
Top 10 Stock Picks of Samuel Isaly’s OrbiMed AdvisorsIn this article, we discuss the top 10 stock picks of Samuel Isaly’s OrbiMed Advisors. If you want to skip our detailed analysis of Isaly’s history, investment philosophy, and hedge fund performance, go directly to Top 5 Stock Picks of Samuel Isaly’s OrbiMed Advisors. Samuel Isaly graduated from Princeton University with an A.B. in Economics […] |
Edgewise Therapeutics to Participate at SVB Leerink 11th Annual Global Healthcare Conference on February 16BOULDER, Colo., February 02, 2022--Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle disorders, announced today that members of its senior management team will participate in a fireside discussion and one-on-one investor meetings at the SVB Leerink Virtual 11th Annual Global Healthcare Conference, on February 16, 2022. |
Edgewise Therapeutics (EWTX) presents Topline results from the Phase 1b study of EDG-5506 - SlideshowNo summary available. |
J.P. Morgan’s 2 Stock Picks With Over 80% Upside PotentialLess than two weeks into the new year, the key question is coming clear: should we buy the dip? The markets are swooning a bit, so far in January. Both the S&P 500 and the NASDAQ are registering losses in 2022’s cumulative trading sessions – 2% on the S&P, and 4.5% on the NASDAQ. A combination of headwinds and tailwinds are pushing on equities. The former include the Omicron wave of COVID-19, as well as ongoing disruptions in the supply chains and labor markets. On the positive side, Omicron is |
EWTX Price Returns
| 1-mo | -24.22% |
| 3-mo | -53.31% |
| 6-mo | -66.81% |
| 1-year | -78.97% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -60.27% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...